{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06413537",
            "orgStudyIdInfo": {
                "id": "SPG601-01"
            },
            "organization": {
                "fullName": "Spinogenix",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study of SPG601 in Adult Men With Fragile X Syndrome",
            "officialTitle": "A Phase 2a, Randomized, Double-Blinded, Study Evaluating the Neurophysiologic vs Clinical Effects of Single-Dose SPG601 and Placebo in Adult Men With Fragile X Syndrome",
            "therapeuticArea": [
                "Rare Diseases"
            ],
            "study": "study-of-in-adult-men-with-fragile-x-syndrome"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07-05",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-02-20",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-09",
            "studyFirstSubmitQcDate": "2024-05-09",
            "studyFirstPostDateStruct": {
                "date": "2024-05-14",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-08",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-09",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Spinogenix",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Avance Clinical Pty Ltd.",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, pharmacokinetics and pharmacodynamics of SPG601 in adult men with Fragile X syndrome.",
            "detailedDescription": "This study is a Phase 2 randomized, double blind, placebo-controlled, cross over, single dose of SPG601 and matching Placebo in patients with Fragile X syndrome.\n\nThis study will entail 2 in person clinic visits to administer oral doses of SPG601 or matching placebo. Participants will receive a dose of either SPG601 or placebo at first visit, and will cross over to receive the other product at the second visit."
        },
        "conditionsModule": {
            "conditions": [
                "Fragile X Syndrome"
            ],
            "keywords": [
                "Fragile X Syndrome",
                "Fragile X Chromosome",
                "cognitive outcomes"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "CROSSOVER",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "maskingDescription": "Double-blinded",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 10,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Experimental: Active SPG601 to be administered to participants with Fragile X Syndrome",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Participants with Fragile X Syndrome will be randomized to receive SPG601 or placebo (8 capsules of 100 mg) one time on days 1 and 8 of the study.",
                    "interventionNames": [
                        "Drug: SPG601"
                    ]
                },
                {
                    "label": "Placebo Comparator: Placebo comparator to be administered to participants with Fragile X Syndrome",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Participants with Fragile X Syndrome will be randomized to receive SPG601 or placebo (8 capsules of 100 mg) one time on days 1 and 8 of the study.",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "SPG601",
                    "description": "synthetic small molecule",
                    "armGroupLabels": [
                        "Experimental: Active SPG601 to be administered to participants with Fragile X Syndrome"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Placebo",
                    "armGroupLabels": [
                        "Placebo Comparator: Placebo comparator to be administered to participants with Fragile X Syndrome"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Clinical Global Impressions Improvement scale as determined by the treating clinician",
                    "description": "Change in clinician rated measures on scale of 1 to 7, higher value indicates more severe symptom presentation",
                    "timeFrame": "15 days"
                },
                {
                    "measure": "Clinical Global Impressions Improvement scale as determined by the caregiver",
                    "description": "Change in caregiver rated measures on scale of 1 to 7, higher value indicates more severe symptom presentation",
                    "timeFrame": "15 days"
                },
                {
                    "measure": "Visual Analog scale as determined by the patient caregiver",
                    "description": "Change in notation on Visual Analog scale as determined by the patient caregiver. Rater will indicate on linear measurement scale of 1 to 100 centimeters, with higher score indicating more severe symptoms",
                    "timeFrame": "15 days"
                },
                {
                    "measure": "Change in auditory response to chirp stimulus",
                    "description": "Auditory test will be evaluated for difference in responses to stimuli.",
                    "timeFrame": "15 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in attention and inhibition symptoms",
                    "description": "KiTAP Tests of Attentional Performance for Children, to measure alertness and assessments of visual reactions",
                    "timeFrame": "15 days"
                },
                {
                    "measure": "Change in cognitive outcomes measured by NIH Cognitive Toolbox",
                    "description": "National Institute of Health (NIH)- Toolbox Cognitive Battery (TCB):\n\nA series of tests will be conducted to assess reading, vocabulary, and speed matching. These tests are scored from zero to 100. A higher score indicate better performance.",
                    "timeFrame": "15 days"
                },
                {
                    "measure": "Change in eye tracking for social gaze",
                    "description": "This test will measure eye tracking and movement in response to stimuli, and social gaze version, with a Likert scale of 1-5 for behavior rating.",
                    "timeFrame": "15 days"
                },
                {
                    "measure": "Change in memory and cognitive assessment with RBANS list learning.",
                    "description": "RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) is scored from -4 to 4, with higher values indicate higher memory and cognitive assessment",
                    "timeFrame": "15 days"
                },
                {
                    "measure": "Change in auditory response to steady state auditory stimuli",
                    "description": "Auditory test will be evaluated for difference in responses to stimuli.",
                    "timeFrame": "15 days"
                },
                {
                    "measure": "Change in eye tracking measured by electroretinography",
                    "description": "This test will measure the electrical activity in the retina in response to stimuli",
                    "timeFrame": "15 days"
                },
                {
                    "measure": "Safety and tolerability of SPG601 in patients with Fragile X Syndrome",
                    "description": "Incidence, nature, and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)",
                    "timeFrame": "15 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult males aged 18 to 45 years\n* Diagnosis of Fragile X as confirmed with genetic testing\n* Patient must have caregiver\n* Must be in good health with no significant medical history\n* Clinical laboratory values within normal range or \\< 1.2 times ULN\n* Contraceptive use by men or women consistent with local regulations\n* Able and willing to provide written informed consent\n* Stable dosing of psychotropic drugs for at least 4 weeks\n\nExclusion Criteria:\n\n* Any physical or psychological condition that prohibits study completion\n* Uncontrolled seizures or history of epilepsy with a seizure in the past 6 months.\n* Auditory or visual impairments that can not be corrected\n* History of suicidal behavior or suicidal ideation\n* Screening vital signs that are abnormal per protocol specification\n* ECG that are clinically significant abnormal\n* History of substance abuse or dependence within 6 months\n* Other investigational products within 30 days",
            "healthyVolunteers": false,
            "sex": "MALE",
            "minimumAge": "18 Years",
            "maximumAge": "45 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Sarah Richter",
                    "role": "CONTACT",
                    "phone": "513-803-3324",
                    "email": "sarah.richter@cchmc.org"
                },
                {
                    "name": "Craig Erickson, MD",
                    "role": "CONTACT",
                    "email": "Craig.Erickson@cchmc.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Craig Erickson, MD",
                    "affiliation": "Children's Hospital Medical Center, Cincinnati",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Cincinnati Children's Hospital Medical Center",
                    "status": "RECRUITING",
                    "city": "Cincinnati",
                    "state": "Ohio",
                    "zip": "45229",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sarah Richter",
                            "role": "CONTACT",
                            "phone": "513-803-3324",
                            "email": "sarah.richter@cchmc.org,"
                        },
                        {
                            "name": "Ashley Dapore",
                            "role": "CONTACT",
                            "email": "ashley.dapore@cchmc.org"
                        },
                        {
                            "name": "Craig A Erikson, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        },
                        {
                            "name": "Ernest Pedapati, MD",
                            "role": "SUB_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.12713,
                        "lon": -84.51435
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000005600",
                    "term": "Fragile X Syndrome"
                },
                {
                    "id": "D000013577",
                    "term": "Syndrome"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004194",
                    "term": "Disease"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000038901",
                    "term": "Mental Retardation, X-Linked"
                },
                {
                    "id": "D000008607",
                    "term": "Intellectual Disability"
                },
                {
                    "id": "D000019954",
                    "term": "Neurobehavioral Manifestations"
                },
                {
                    "id": "D000009461",
                    "term": "Neurologic Manifestations"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000025064",
                    "term": "Sex Chromosome Disorders"
                },
                {
                    "id": "D000025063",
                    "term": "Chromosome Disorders"
                },
                {
                    "id": "D000000013",
                    "term": "Congenital Abnormalities"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                },
                {
                    "id": "D000040181",
                    "term": "Genetic Diseases, X-Linked"
                },
                {
                    "id": "D000020271",
                    "term": "Heredodegenerative Disorders, Nervous System"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "asFound": "Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8721",
                    "name": "Fragile X Syndrome",
                    "asFound": "Fragile X Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11589",
                    "name": "Intellectual Disability",
                    "relevance": "LOW"
                },
                {
                    "id": "M24774",
                    "name": "Mental Retardation, X-Linked",
                    "relevance": "LOW"
                },
                {
                    "id": "M21826",
                    "name": "Neurobehavioral Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "M12404",
                    "name": "Neurologic Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "M23023",
                    "name": "Chromosome Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M23024",
                    "name": "Sex Chromosome Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M12",
                    "name": "Congenital Abnormalities",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "M24877",
                    "name": "Genetic Diseases, X-Linked",
                    "relevance": "LOW"
                },
                {
                    "id": "M22092",
                    "name": "Heredodegenerative Disorders, Nervous System",
                    "relevance": "LOW"
                },
                {
                    "id": "T2370",
                    "name": "Fragile X Syndrome",
                    "asFound": "Fragile X Syndrome",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}